Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sitagliptin in patients with recently diagnosed type 2 diabetes mellitus.
Study InterventionsTirzepatide, Pioglitazone, SitagliptinPrimary Endpointsnumber of subjects achieving HbA1c <6.5% at 6 months (Efficacy); Number of subjects failing to achieving HbA1c <6.5% Long-termStudy Period2024-11-07 → 2029-06-30 Dietary Peanuts and Nutrition-Related Outcomes
This study will look at how eating peanuts every day might affect participants weight, how healthy their diet is, and how they feel when eating. Investigators want to see if adding peanuts to meals for 12 weeks helps participants feel fuller, have more energy, and improve body composition. The study will include adults who have been taking GLP-1 medicines like semaglutide or tirzepatide for at lea
Study InterventionsPeanuts, Dual-energy X-ray absorptiometry (DEXA) scansPrimary EndpointsChange is Satiety as measured by the Hunger and Satiety Visual Analog Scales (VAS); Change in fatigue as measured by the Fatigue Severity VAS-F SurveyStudy Period2026-04-20 → 2027-12 CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry
CARTIZ is a prospective observational clinical registry of adults in Mexico receiving tirzepatide (a dual GLP-1/GIP receptor agonist) under an independent clinical indication - typically type 2 diabetes, insulin resistance, obesity, renal protection, metabolic hypertension, or associated off-label metabolic use. The registry is entirely observational: CARTIZ does not initiate, modify, interrupt, o
Study InterventionsTirzepatidePrimary EndpointsACR20 response rate at Week 4 in the Mechanistic Analysis Set; Proportion of Week-4 ACR20 response mediated by biomarker panel in the Mechanistic Analysis SetStudy Period2026-05 → 2029-05 A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.
Study InterventionsTirzepatide, PlaceboPrimary EndpointsChange From Baseline to Week 18 in Sleep Metabolic Rate (SMR)Study Period2020-07-09 → 2022-05-26 Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).
Study InterventionsGZR18, TirzepatidePrimary EndpointsPrimary ObjectiveStudy Period2025-02-12 → 2026-06-22 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy of the study drug tirzepatide in participants with type 2 diabetes mellitus.
Study Interventionstirzepatide, Dulaglutide, PlaceboPrimary EndpointsChange From Baseline to Week 26 in Hemoglobin A1c (HbA1c) Bayesian Dose ResponseStudy Period2017-05-24 → 2018-08-01 Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Study InterventionsTirzepatide, DulaglutidePrimary EndpointsFirst occurence of MACE (all-cause mortailty, myocardial infarction, or death)Study Period2024-10-01 → 2025-07-30 A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus (DM). The study comprises of a 4-week screening period; a 48-week core treatment period, w
Study InterventionsRO7204239, RO7204239 Matching Placebo, TirzepatidePrimary EndpointsPercent Change From Baseline in Body WeightStudy Period2025-05-05 → 2027-07-23 A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
Study InterventionsTirzepatide, SemaglutidePrimary EndpointsChange From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)Study Period2019-07-30 → 2021-02-15 A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
Study InterventionsTirzepatide, PlaceboPrimary EndpointsPercentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver HistologyStudy Period2019-11-19 → 2024-01-10